Welcome of the chairs
H. Gisslinger, J. Schwarz
MPNs in 2024
F. Heidel
R. Kušec, M. Lucijanic
Introduction by the chair
State of the art in hematology diagnosis
T. Haferlach
Exploring the Initial Stages of MPNs: Diagnostic and Clinical Implications in PV, ET and PMF
T. Barbui
Machine learning
D. Royston
J.J. Kiladjian, A. Reiter
Introduction by the chair
Chronic inflammation and mut. acquisition
H. Hasselbalch
Mut. allele burden and its clinical relevance
R. Skoda
Discussion about clinical relevance
all
BREAK
M. Doubek, M. Egyed
Introduction by the chair
Management of pediatric patients
N. Kucine
Management of young adult patients
M. Sobas
BREAK
From low-risk to high-risk
A. Reiter
How I treat PV
H. Gisslinger
MF
F. Passamonti
MDS
S. De Botton
BREAK
COMORBIDITIES & DRUG TOXICITIES – HOW TO HANDLE – PANEL DISCUSSION
M. Griesshammer, H Gisslinger
Introduction by the chair
Impulse lecture
R. Silver
Panel discussion
A. Hatalova, H. Gisslinger A. Luger, V. Buxhofer-Ausch
P. le Coutre, A. Hochhaus
Introduction by the chair
CML update 2024
P. te Boekhorst
Role of IFN in CML
A. Hochhaus
BREAK
J. Schwarz, A. Hatálová
Introduction by the chair
Challenges in the introduction of novel treatment modalities for MPN
R. Kralovics
Ongoing clinical research
J.J. Kiladjian
Farewell on behalf of CEMPO
H. Gisslinger
